Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - clarithromycin -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; hypromellose; titanium dioxide; iron oxide yellow; magnesium stearate; macrogol 8000; microcrystalline cellulose - clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. acute streptococcal pharyngitis 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts < 75 cells/mm3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila 3. skin and skin structure infections (e.g. impetigo) 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3 there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; iron oxide yellow; macrogol 8000; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide - clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. acute streptococcal pharyngitis 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts < 75 cells/mm3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila 3. skin and skin structure infections (e.g. impetigo) 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3 there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Malta - Kiingereza - Medicines Authority

wockhardt uk limited - clarithromycin - film-coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - Kiingereza - Medicines Authority

wockhardt uk limited - clarithromycin - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - Kiingereza - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clarithromycin - film-coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - Kiingereza - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clarithromycin - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

accord healthcare limited - clarithromycin - film coated tablet - 250 milligram - clarithromycin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

accord healthcare limited - clarithromycin - film coated tablet - 500 milligram - clarithromycin

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

max health limited - clarithromycin 500mg - powder for infusion concentrate - 500 mg - active: clarithromycin 500mg excipient: lactobionic acid - clarithromycin intravenous infusion is indicated whenever parenteral therapy is required for treatment of sensitive microorganisms in the following conditions: · upper respiratory tract infections · lower respiratory tract infections · skin and soft tissue infections